Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.

Phase 4

Completed

• Conditions: Seizures

• Registration Number: NCT00141427
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Study First Submitted: 2005-08-31
• Study First Submitted QC: 2005-08-31
• Study First Posted: 2005-09-01
• Study Completion: 2006-05
• Status Verified: 2006-06
• Last Update Submitted: 2021-01-21
• Last Update Posted: 2021-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 540

Inclusion Criteria

• Male and female subjects with a diagnosis of partial epilepsy.
• 18 years and older.

Exclusion Criteria

• Having a treatable cause of seizure.
• Having a progressive neurological or systemic disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Reduction in seizure frequency.

Trial Locations

Locations (1)

Pfizer Investigational Site